Musa Tariq Sells 1,951 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 1,951 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total value of $255,893.16. Following the transaction, the director owned 11,048 shares in the company, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $130.19, for a total transaction of $15,102.04.
• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $95.96, for a total transaction of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total transaction of $9,840.28.

Guardant Health Price Performance

Shares of GH opened at $136.96 on Thursday. The company has a market capitalization of $18.16 billion, a PE ratio of -40.40 and a beta of 1.61. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $141.07. The company’s fifty day moving average price is $110.21 and its 200 day moving average price is $103.42.

Analyst Ratings Changes

A number of equities analysts have recently commented on GH shares. Royal Bank Of Canada assumed coverage on Guardant Health in a research note on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price objective on the stock. Mizuho increased their target price on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Piper Sandler set a $127.00 price target on Guardant Health in a research report on Thursday, May 21st. Finally, Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $142.19.

Hedge Funds Weigh In On Guardant Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Western Wealth Management LLC bought a new stake in shares of Guardant Health in the 1st quarter worth approximately $125,000. Perceptive Advisors LLC increased its position in shares of Guardant Health by 87.5% during the first quarter. Perceptive Advisors LLC now owns 300,000 shares of the company’s stock valued at $27,711,000 after purchasing an additional 140,000 shares during the period. BankChampaign National Association bought a new stake in shares of Guardant Health during the first quarter valued at approximately $809,000. Hamilton Wealth LLC raised its stake in shares of Guardant Health by 103.0% in the first quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock valued at $7,085,000 after purchasing an additional 38,916 shares in the last quarter. Finally, Edgestream Partners L.P. raised its stake in shares of Guardant Health by 321.6% in the first quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock valued at $2,980,000 after purchasing an additional 24,606 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.